{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:21:47Z","timestamp":1765808507918,"version":"build-2065373602"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ovarian cancer is the second deadliest gynecologic malignancy globally. The current standard of care first-line therapy for newly diagnosed advanced epithelial ovarian cancer is surgery and platinum-based chemotherapy (\u00b1bevacizumab), followed by maintenance therapy with a poly(ADP-ribose) polymerase (PARP) inhibitor, bevacizumab, or a combination of the two. Although anti-programmed cell death (PD) protein 1 and anti\u2013PD ligand 1 antibodies (PD-[L]1 inhibitors) have shown benefit in several solid tumors, their effect in ovarian cancer remains uncertain. Several trials are evaluating PD-(L)1 inhibitors in combination with first-line platinum-based chemotherapy and PARP inhibitor maintenance treatment. Here, we review trial designs to understand key similarities and differences for future assessments of the results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>The clinical trials registry \u201cClinicalTrials.gov\u201d was searched using keywords, including ovarian cancer and niraparib, olaparib, or rucaparib. Search results were then filtered for phase 3 and manually reviewed to identify trials evaluating combinations of PARP inhibitors and PD-(L)1 inhibitors in the first-line setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four trials, ENGOT-OV44\/FIRST (NCT03602859), ENGOT-OV46\/AGO-OVAR 23\/GOG-3025\/DUO-O (NCT03737643), ENGOT-OV43\/GOG-3036\/KEYLYNK-001 (NCT03740165), and ENGOT-OV45\/GOG-3020\/ATHENA (NCT03522246), were identified. Of these, FIRST, DUO-O, and KEYLYNK-001 are evaluating both first-line use in combination with chemotherapy and maintenance, whereas ATHENA focuses on maintenance after a response to chemotherapy; however, DUO-O and KEYLYNK-001 do not include a PARP inhibitor in the comparator arm, limiting the ability to compare the added benefit of immunotherapy over the current standard of care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Results of these trials will determine whether PARP inhibitor and PD-(L)1 inhibitor combination with or without bevacizumab can improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf270","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:44:09Z","timestamp":1757763849000},"source":"Crossref","is-referenced-by-count":2,"title":["Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4808-3805","authenticated-orcid":false,"given":"B J","family":"Rimel","sequence":"first","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center , Los Angeles, CA 90048,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Pujade-Lauraine","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, H\u00f4pital H\u00f4tel-Dieu, University of Paris , Paris 75004,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center , Oklahoma City, OK 73104,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacobus","family":"Pfisterer","sequence":"additional","affiliation":[{"name":"AGO Study Group , Wiesbaden 65185,","place":["Germany"]},{"name":"Department of Gynecological Oncology, Gynecologic Oncology Center , Kiel 24105,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7476-3372","authenticated-orcid":false,"given":"Sileny","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Universitair Ziekenhuis Leuven , Leuven 3000,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cibula","sequence":"additional","affiliation":[{"name":"Department of Gynaecology, Obstetrics and Neonatology First Faculty of Medicine, Charles University, Prague 116 36; and General University Hospital in Prague , Prague 128 08,","place":["Czech Republic"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Reyners","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Groningen, University of Groningen , Groningen 9700 RB,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Redondo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario La Paz-IdiPAZ and GEICO , Madrid 28046,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Papadimitriou","sequence":"additional","affiliation":[{"name":"HeCOG and Oncology Unit, Aretaieion University Hospital, National and Kapodistrian University of Athens , Athens 115 28,","place":["Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram","family":"Eitan","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Division, Rabin Medical Center , Petah Tikva 4941492,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[{"name":"Uro-Gynecologic Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione G Pascale , Naples 80131,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalind","family":"Glasspool","sequence":"additional","affiliation":[{"name":"Beatson West of Scotland Cancer Centre and School of Cancer Sciences, University of Glasgow , Glasgow G12 0YN,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansoor Raza","family":"Mirza","sequence":"additional","affiliation":[{"name":"Department of Cancer Treatment, Rigshospitalet\u2014Copenhagen University Hospital , Copenhagen 2100,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubomir","family":"Bodnar","sequence":"additional","affiliation":[{"name":"Faculty of Medical and Health Sciences, University of Siedlce , Siedlce 08-110,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Duska","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Virginia School of Medicine , Charlottesville, VA 22903,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Provencher","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Universit\u00e9 de Montr\u00e9al , Montreal, Quebec H2X 3E4,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9b\u00e9cca","family":"Pha\u00ebton","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, GSK, Collegeville , PA 19426,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjinder","family":"Bains","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, GSK , London W4 2HD,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif","family":"Coskuncay","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, GSK , London W4 2HD,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Claire","family":"Hardy-Bessard","sequence":"additional","affiliation":[{"name":"Oncologie M\u00e9dicale, Centre CARIO , Pl\u00e9rin Sur Mer , Pl\u00e9rin 22190,","place":["France"]},{"name":"\u2014HPCA, and Groupe d\u2019Investigateurs Nationaux pour l\u2019Etude des Cancers Ovariens (GINECO) , Pl\u00e9rin Sur Mer , Pl\u00e9rin 22190,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"2025103119565058700_oyaf270-B1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025103119565058700_oyaf270-B2","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.3390\/curroncol31070283","article-title":"The complex tumor microenvironment in ovarian cancer: therapeutic challenges and opportunities","volume":"31","author":"Garlisi","year":"2024","journal-title":"Curr Oncol"},{"key":"2025103119565058700_oyaf270-B3","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2025103119565058700_oyaf270-B4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonzalez-Martin","year":"2023","journal-title":"Ann Oncol"},{"key":"2025103119565058700_oyaf270-B5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","article-title":"Global epidemiology of epithelial ovarian cancer","volume":"21","author":"Webb","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2025103119565058700_oyaf270-B6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13048-019-0579-0","article-title":"Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives\u2014a review","volume":"12","author":"Gupta","year":"2019","journal-title":"J Ovarian Res"},{"key":"2025103119565058700_oyaf270-B7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.gore.2019.07.007","article-title":"BRCA mutation in high grade epithelial ovarian cancers","volume":"29","author":"Manchana","year":"2019","journal-title":"Gynecol Oncol Rep"},{"key":"2025103119565058700_oyaf270-B8","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov"},{"key":"2025103119565058700_oyaf270-B9","first-page":"100629","article-title":"Epithelial ovarian cancer: review article","volume":"33","author":"Sambasivan","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"2025103119565058700_oyaf270-B10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2021 update","volume":"155","author":"Berek","year":"2021","journal-title":"Int J Gynaecol Obstet"},{"key":"2025103119565058700_oyaf270-B11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/AOG.0000000000004173","article-title":"Updates and new options in advanced epithelial ovarian cancer treatment","volume":"137","author":"Kurnit","year":"2021","journal-title":"Obstet Gynecol"},{"key":"2025103119565058700_oyaf270-B12","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann Oncol"},{"year":"2023","author":"Roche Registration GmbH","key":"2025103119565058700_oyaf270-B13"},{"year":"2022","author":"Genentech Inc","key":"2025103119565058700_oyaf270-B14"},{"key":"2025103119565058700_oyaf270-B15","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"2025103119565058700_oyaf270-B16","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"2025103119565058700_oyaf270-B17","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025103119565058700_oyaf270-B18","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025103119565058700_oyaf270-B19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2015.07.103","article-title":"Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology\/GOG study","volume":"139","author":"Ferriss","year":"2015","journal-title":"Gynecol Oncol"},{"key":"2025103119565058700_oyaf270-B20","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2025103119565058700_oyaf270-B21","doi-asserted-by":"crossref","first-page":"e450s","DOI":"10.6061\/clinics\/2018\/e450s","article-title":"Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management","volume":"73","author":"da Cunha Colombo Bonadio","year":"2018","journal-title":"Clinics (Sao Paulo)"},{"key":"2025103119565058700_oyaf270-B22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s12276-021-00557-3","article-title":"Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance","volume":"53","author":"Kim","year":"2021","journal-title":"Exp Mol Med"},{"year":"2023","author":"AstraZeneca","key":"2025103119565058700_oyaf270-B23"},{"key":"2025103119565058700_oyaf270-B24","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ygyno.2024.05.014","article-title":"Trends in estimated PARP inhibitor eligibility and benefit among US epithelial ovarian cancer patients","volume":"187","author":"Carballo","year":"2024","journal-title":"Gynecol Oncol"},{"key":"2025103119565058700_oyaf270-B25","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"2025103119565058700_oyaf270-B26","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"2025103119565058700_oyaf270-B27","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"year":"2024","author":"GSK","key":"2025103119565058700_oyaf270-B28"},{"key":"2025103119565058700_oyaf270-B29","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"2025103119565058700_oyaf270-B30","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann Oncol"},{"year":"2024","author":"pharma & GmbH","key":"2025103119565058700_oyaf270-B31"},{"year":"2023","author":"European Medicines Agency","key":"2025103119565058700_oyaf270-B32"},{"key":"2025103119565058700_oyaf270-B33","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA\u2013MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025103119565058700_oyaf270-B34","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ygyno.2024.07.022","article-title":"Interim post-progression data and updated survival in patients with newly diagnosed advanced ovarian cancer in ATHENA-MONO","volume":"190","author":"Kristeleit","year":"2024","journal-title":"Gynecol Oncol"},{"key":"2025103119565058700_oyaf270-B35","doi-asserted-by":"crossref","first-page":"viii51","DOI":"10.1093\/annonc\/mdx441","article-title":"Treatment of recurrent ovarian cancer","volume":"28","author":"Pignata","year":"2017","journal-title":"Ann Oncol"},{"key":"2025103119565058700_oyaf270-B36","doi-asserted-by":"crossref","first-page":"100536","DOI":"10.1016\/j.esmoop.2022.100536","article-title":"Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?","volume":"7","author":"Musacchio","year":"2022","journal-title":"ESMO Open"},{"key":"2025103119565058700_oyaf270-B37","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.3390\/cancers15123220","article-title":"Chasing immune checkpoint inhibitors in ovarian cancer: novel combinations and biomarker discovery","volume":"15","author":"Colombo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025103119565058700_oyaf270-B38","doi-asserted-by":"crossref","first-page":"8519","DOI":"10.1021\/acs.jmedchem.4c00568","article-title":"Emerging targets and therapeutics in immuno-oncology: insights from landscape analysis","volume":"67","author":"Iyer","year":"2024","journal-title":"J Med Chem"},{"key":"2025103119565058700_oyaf270-B39","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"2025103119565058700_oyaf270-B40","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025103119565058700_oyaf270-B41","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025103119565058700_oyaf270-B42","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ygyno.2023.06.018","article-title":"Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050\/GOG 3015\/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III\/IV ovarian cancer","volume":"177","author":"Pignata","year":"2023","journal-title":"Gynecol Oncol"},{"key":"2025103119565058700_oyaf270-B43","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025103119565058700_oyaf270-B44","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1200\/JCO.21.00334","article-title":"Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA)","volume":"39","author":"Hamanishi","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025103119565058700_oyaf270-B45","doi-asserted-by":"crossref","first-page":"LBA5501","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5501","article-title":"LBA5501 Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: final overall and progression-free survival results from the AGO-OVAR 2.29\/ENGOT-ov34 study","volume":"42","author":"Marm\u00e9","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025103119565058700_oyaf270-B46","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1200\/JCO.23.00529","article-title":"Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase III ATALANTE\/ENGOT-ov29 trial","volume":"41","author":"Kurtz","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025103119565058700_oyaf270-B47","first-page":"A4","article-title":"PO005LBA\/#1579 a randomized, phase\/study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009)","volume":"33","author":"O\u2019Cearbhaill","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"2025103119565058700_oyaf270-B48","doi-asserted-by":"crossref","first-page":"107952","DOI":"10.1016\/j.isci.2023.107952","article-title":"Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design","volume":"26","author":"Li","year":"2023","journal-title":"iScience"},{"key":"2025103119565058700_oyaf270-B49","doi-asserted-by":"crossref","first-page":"1179554921996288","DOI":"10.1177\/1179554921996288","article-title":"The synergistic effect of PARP inhibitors and immune checkpoint inhibitors","volume":"15","author":"Wu","year":"2021","journal-title":"Clin Med Insights Oncol"},{"key":"2025103119565058700_oyaf270-B50","doi-asserted-by":"crossref","first-page":"S1278","DOI":"10.1016\/j.annonc.2023.10.031","article-title":"LBA37 atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) &gt;6 months: primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41\/GEICO 69-O\/ANITA phase III trial","volume":"34","author":"Gonzalez Martin","year":"2023","journal-title":"Ann Oncol"},{"key":"2025103119565058700_oyaf270-B51","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/1078-0432.CCR-23-2249","article-title":"Olaparib plus durvalumab, with or without bevacizumab, as treatment in PARP inhibitor-na\u00efve platinum-sensitive relapsed ovarian cancer: a phase II multi-cohort study","volume":"30","author":"Drew","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025103119565058700_oyaf270-B52","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3389\/fcell.2020.00758","article-title":"Tumor microenvironment in ovarian cancer: function and therapeutic strategy","volume":"8","author":"Yang","year":"2020","journal-title":"Front Cell Dev Biol"},{"year":"2024","author":"ClinicalTrials.gov. identifier: NCT03602859","key":"2025103119565058700_oyaf270-B53"},{"year":"2024","author":"ClinicalTrials.gov. identifier: NCT03737643","key":"2025103119565058700_oyaf270-B54"},{"year":"2024","author":"ClinicalTrials.gov. identifier: NCT03740165","key":"2025103119565058700_oyaf270-B55"},{"year":"2024","author":"Clintrials.gov Identifier: NCT03522246","key":"2025103119565058700_oyaf270-B56"},{"key":"2025103119565058700_oyaf270-B57","doi-asserted-by":"crossref","first-page":"S1223","DOI":"10.1016\/j.annonc.2024.08.2269","article-title":"LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC)","volume":"35","author":"Monk","year":"2024","journal-title":"Ann Oncol"},{"key":"2025103119565058700_oyaf270-B58","first-page":"1","article-title":"Durvalumab + carboplatin\/paclitaxel + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance for newly diagnosed advanced ovarian cancer without a tumour BRCA1\/BRCA2 mutation: updated results from DUO-O","volume":"9","author":"Trillsch","year":"2024","journal-title":"Ann Oncol"},{"key":"2025103119565058700_oyaf270-B59","first-page":"IX89","article-title":"ENGOT-ov43\/KEYLYNK-001: a phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA\u00ac-nonmutated advanced epithelial ovarian cancer","volume":"30","author":"Fujiwara","year":"2019","journal-title":"Ann Oncol"},{"key":"2025103119565058700_oyaf270-B60","doi-asserted-by":"crossref","first-page":"LBA5506","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5506","article-title":"Durvalumab with paclitaxel\/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1\/2 mutation (non-tBRCAm): results from the randomized, placebo (pbo)-controlled phase III. DUO-O trial","volume":"41","author":"Harter","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025103119565058700_oyaf270-B61","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24031973","article-title":"Predicting prognosis and platinum resistance in ovarian cancer: role of immunohistochemistry biomarkers","volume":"24","author":"Atallah","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025103119565058700_oyaf270-B62","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/ijgc-2022-003658","article-title":"Targeted therapy for mucinous ovarian carcinoma: evidence from clinical trials","volume":"33","author":"Nugawela","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"2025103119565058700_oyaf270-B63","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10110433","article-title":"Cell origins of high-grade serous ovarian cancer","volume":"10","author":"Kim","year":"2018","journal-title":"Cancers (Basel)"},{"key":"2025103119565058700_oyaf270-B64","doi-asserted-by":"crossref","first-page":"TPS6101","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS6101","article-title":"ENGOT-OV44\/FIRST study: a randomized, double-blind, adaptive, phase III study of standard of care (SOC) platinum-based therapy \u00b1 dostarlimab followed by niraparib \u00b1 dostarlimab maintenance as first-line (1L) treatment of stage 3 or 4 ovarian cancer (OC)","volume":"38","author":"Hardy-Bessard","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025103119565058700_oyaf270-B65","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/ijgc-2021-002933","article-title":"ATHENA (GOG-3020\/ENGOT-ov45): a randomized, phase. Trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer","volume":"31","author":"Monk","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"2025103119565058700_oyaf270-B66","doi-asserted-by":"crossref","first-page":"TPS5598","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS5598","article-title":"DUO-O: a randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients","volume":"37","author":"Harter","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025103119565058700_oyaf270-B67","doi-asserted-by":"crossref","first-page":"499","DOI":"10.20517\/cdr.2023.08","article-title":"The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities","volume":"6","author":"Zielli","year":"2023","journal-title":"Cancer Drug Resist"},{"key":"2025103119565058700_oyaf270-B68","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2018.08.036","article-title":"Exploratory outcome analyses according to stage and\/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer","volume":"152","author":"Gonz\u00e1lez Mart\u00edn","year":"2019","journal-title":"Gynecol Oncol"},{"key":"2025103119565058700_oyaf270-B69","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.22.01207","article-title":"Identification of patients with ovarian cancer experiencing the highest benefit from bevacizumab in the first-line setting on the basis of their tumor-intrinsic chemosensitivity (KELIM): the GOG-0218 validation study","volume":"40","author":"You","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025103119565058700_oyaf270-B70","doi-asserted-by":"crossref","first-page":"pkaa026","DOI":"10.1093\/jncics\/pkaa026","article-title":"Bevacizumab for newly diagnosed ovarian cancers: best candidates among high-risk disease patients (ICON-7)","volume":"4","author":"Colomban","year":"2020","journal-title":"JNCI Cancer Spectr"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf270\/64302287\/oyaf270.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf270\/64302287\/oyaf270.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf270\/64302287\/oyaf270.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T23:57:04Z","timestamp":1761955024000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf270\/8256688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":70,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf270","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,17]]},"article-number":"oyaf270"}}